Want to see SGMOQ full AI Analyst Report?
SGMOQ Stock Chart & Stats
$0.26
-$0.13(-9.49%)
At close: 4:00 PM EST
$0.26
-$0.13(-9.49%)
Day’s Range― - ―
52-Week Range$0.03 - $0.77
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.65M
Market Cap
$23.61M
Enterprise Value$65.70M
Total Cash (Recent Filing)$27.59M
Total Debt (Recent Filing)$19.33M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding414,288,850
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap2.78
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$2.00Price Target Upside669.23% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$9.95M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSangamo reports very high gross margins (~74% TTM), reflecting low direct cost for its partnership/licensing revenue mix. Durable high margins mean incremental revenue can disproportionately improve operating leverage if commercial milestones or partner deals materialize, supporting future profitability once scale and revenue cadence stabilize.
Regulatory Clarity For ST-920FDA alignment on an accelerated approval pathway and use of 52‑week eGFR slope with 104‑week confirmatory data materially reduces late‑stage regulatory uncertainty for ST‑920. This structural clarity lowers development risk and shortens possible commercialization timelines, improving the long‑term odds of milestone realization and partner monetization.
Platform & Pipeline ProgressSangamo’s zinc‑finger and MINT platform advances, accepted abstracts and multiple active programs (BLA modules submitted, neurology site activations, GLP toxicology completed) indicate a diversified pipeline and proprietary capabilities. These durable technology assets support partnership potential, multiple commercialization pathways and reduce single‑asset binary risk over time.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow (~-$90M TTM) indicates the company cannot self‑fund development and is structurally dependent on external financing or partner payments. Over months, this raises execution risk, increases likelihood of dilutive financings, and can delay or constrain R&D and regulatory milestones if capital access tightens.
Weakened Balance Sheet / Negative EquityEquity turning negative and a contraction in total assets materially reduce financial flexibility and increase creditor and dilution risk. Structurally weaker capital structure limits options for non‑dilutive funding, raises cost of capital, and can hinder the company's ability to execute licensing, manufacturing scale‑up, or commercial launches without significant restructuring or asset sales.
Chapter 11 / OTC Transition And Delisting RiskThe Chapter 11 filing and shift to OTC trading create lasting impairment to liquidity, institutional access and dealmaking visibility. Over months, this structural market and listing uncertainty can impede strategic partnerships, make fundraising more costly or infeasible, and materially constrain the company’s ability to execute its development and commercialization plans.
Sangamo Therapeutics News
SGMOQ FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
Sangamo Therapeutics lowest stock price was $0.03 and its highest was $0.77 in the past 12 months.
What is Sangamo Therapeutics’s market cap?
Sangamo Therapeutics’s market cap is $23.61M.
When is Sangamo Therapeutics’s upcoming earnings report date?
Sangamo Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.
How were Sangamo Therapeutics’s earnings last quarter?
Sangamo Therapeutics released its earnings results on May 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.085.
Is Sangamo Therapeutics overvalued?
According to Wall Street analysts Sangamo Therapeutics’s price is currently Undervalued.
Does Sangamo Therapeutics pay dividends?
Sangamo Therapeutics does not currently pay dividends.
What is Sangamo Therapeutics’s EPS estimate?
Sangamo Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Sangamo Therapeutics have?
Sangamo Therapeutics has 414,288,850 shares outstanding.
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Sangamo Therapeutics reported an EPS of -$0.08 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sangamo Therapeutics?
Currently, no hedge funds are holding shares in SGMOQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sangamo Therapeutics
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation to achieve its objectives. A cornerstone of Sangamo's approach is its proprietary zinc finger protein (ZFP) technology platform. This platform facilitates the creation of zinc finger nucleases, which are specialized proteins capable of precisely altering DNA sequences by either inserting or inactivating specific genes. Furthermore, it produces ZFP transcription factors, proteins designed to modulate (increase or decrease) gene expression. Sangamo has a robust clinical pipeline, with key programs progressing through various stages. SB-525 is currently in the Phase III AFFINE clinical trial for the treatment of hemophilia A. Their gene therapy candidate, ST-920, is undergoing Phase I/II STAAR clinical trials for Fabry disease, while the cell therapy SAR445136 is being evaluated in Phase I/II PRECIZN-1 clinical trials for sickle cell disease. The company's development efforts also extend to other therapeutic areas, including TX200, a chimeric antigen receptor for addressing HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502, which is aimed at treating synucleinopathies like Parkinson's disease and other neuromuscular disorders. Sangamo has established numerous collaborative and strategic partnerships with leading entities such as Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and the California Institute for Regenerative Medicine. Established in 1995, the company was initially known as Sangamo BioSciences, Inc. It subsequently adopted its current name, Sangamo Therapeutics, Inc., in January 2017. The corporate headquarters are situated in Brisbane, California.
SGMOQ Company Deck
SGMOQ Earnings Call
Q1 2026
0:00 / 0:00
SGMOQ Stock 12 Month Forecast
Average Price Target
$2.00
▲(669.23% Upside)
Technical Analysis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Ownership Overview
0.94% Insiders
5.59% Mutual Funds
11.71% Other Institutional Investors
81.76% Public Companies and
Individual Investors